Global Primary Ciliary Dyskinesia (PCD) Market Projected to Grow at 6.6% CAGR, Reaching $0.64 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Primary Ciliary Dyskinesia (PCD) Industry Market Size Be by 2025?
The market size for primary ciliary dyskinesia (pcd) has seen robust growth in the past few years. The market is projected to expand from a valuation of $0.46 billion in 2024 to $0.49 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. This growth during the historical period is accredited to factors such as increased misdiagnoses with other respiratory issues, higher dependency on symptom-oriented treatments, rise in utilization of standard respiratory therapies, growth in diagnosis via exclusion criteria, and an escalating attention on cystic fibrosis overshadowing primary ciliary dyskinesia.

What's the Long-Term Growth Forecast for the Primary Ciliary Dyskinesia (PCD) Market Size Through 2029?
The market for primary ciliary dyskinesia (pcd) is forecasted to experience robust growth in the coming years, with the market projected to expand to $0.64 billion by 2029, boasting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this anticipated growth within the forecast period include increased understanding of rare respiratory conditions, enhanced access to genetic screening, a surge in incidences of prolonged respiratory infections, more favorable reimbursement strategies, and the proliferation of dedicated diagnostic establishments. Key trends expected to shape the forecast period imagine advancements in genetic mapping technologies, the creation of non-invasive diagnostic instruments, a rise in collaborative research and development efforts, breakthroughs in airway cleaning devices, and the incorporation of artificial intelligence within diagnostic imaging.

View the full report here:
https://www.thebusinessresearchcompany.com/report/primary-ciliary-dyskinesia-pcd-global-market-report

What Are the Key Growth Drivers Fueling the Primary Ciliary Dyskinesia (PCD) Market Expansion?
The increasing interest in gene therapy is predicted to spur the expansion of the primary ciliary dyskinesia market. Gene therapy, which involves altering or replacing defective genes in a patient's cells to treat or avert diseases, is experiencing heightened demand as advancements in genetic research help to facilitate more precise treatments. These treatments focus on rectifying genetic disorders at the molecular level, thereby improving patient prognoses. Scientists are in the process of creating gene therapy for Primary Ciliary Dyskinesia (PCD) to rectify the genetic mutations that are responsible for improper cilia functionality within the respiratory system. The treatment introduces healthy genes to recover normal ciliary movement and improve mucus clearance, thus reducing respiratory infections. For example, the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the United States, reported that as of July 2023, the first quarter of that year saw 247 Phase II clinical trials for gene therapy, a number that has risen by 5%, culminating in a total of 260 ongoing Phase II gene therapy trials by the end of the second quarter. Consequently, the growing demand for gene therapy is fuelling the expansion of the primary ciliary dyskinesia market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24386&type=smp

What Long-Term Trends Will Define the Future of the Primary Ciliary Dyskinesia (PCD) Market?
Leading organizations within the primary ciliary dyskinesia market are concentrating on the creation of unique solutions, such as experimental mRNA-based drugs, with a view to better manage symptoms and enhance the standard of life for patients. An experimental mRNA-based drug is a new form of therapy that uses messenger RNA to instruct cells to generate proteins that can potentially treat or even divert diseases. This advanced technique gets to the heart of conditions at the molecular level, laying the groundwork for customized treatments. For instance, ReCode Therapeutics, Inc., a biotech firm based in the U.S., unveiled RCT1100, an experimental inhaled mRNA therapy, in June 2024. The treatment won approval from the FDA for its special status as an orphan drug to tackle primary ciliary dyskinesia. By delivering DNAI1 mRNA straight to the cells of the airway, RCT1100 aims to restore the ciliary function and address an urgent need that has yet to be met for the roughly 45,000 individuals affected in the U.S., given the lack of current treatments or cures for PCD.

How Is the Primary Ciliary Dyskinesia (PCD) Market Segmented?
The primary ciliary dyskinesia (pcd) market covered in this report is segmented -

1) By Treatment: Antibiotics, Airway Clearance Therapies, Surgical Interventions, Other Treatments
2) By Method: Genetic Testing, Imaging Techniques, Clinical Evaluation, Lung Function Tests
4) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Retail Pharmacies
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Laboratories, Other End-Users

Subsegments:
1) By Antibiotics: Macrolides, Penicillins, Cephalosporins, Fluoroquinolones, Aminoglycosides
2) By Airway Clearance Therapies: Chest Physiotherapy, High-Frequency Chest Wall Oscillation (HFCWO), Positive Expiratory Pressure (PEP) Therapy, Intrapulmonary Percussive Ventilation (IPV), Oscillatory Positive Expiratory Pressure (OPEP)
3) By Surgical Interventions: Sinus Surgery, Tympanostomy Tube Placement, Lung Transplantation
4) By Other Treatments: Mucolytics, Immunomodulatory Therapies, Gene Therapy, Stem Cell Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24386&type=smp

Which Companies Are Leading the Charge in Primary Ciliary Dyskinesia (PCD) Market Innovation?
Major companies operating in the primary ciliary dyskinesia (PCD) market are Centogene N.V., Nationwide Children's Hospital, Revvity Inc., Quest Diagnostics Incorporated, Children's Healare of Atlanta, Exact Sciences Corp., University Hospital Southampton, UT Health East Texas, Guy's and St Thomas' NHS Foundation Trust, National Jewish Health, Vanderbilt University Medical Center, UNC School of Medicine, Stanford Medicine, Mayo Foundation for Medical Education and Research, DNA Labs India Pvt. Ltd., Parion Sciences Inc., ReCode Therapeutics Inc., University Hospital Münster, UAB Health System, PCD Foundatio

Which Regions Are Leading the Global Primary Ciliary Dyskinesia (PCD) Market in Revenue?
North America was the largest region in the primary ciliary dyskinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary ciliary dyskinesia (PCD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24386

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.